Abstract
The topic of this review covers a very important branch of cancer research, cancer vaccination. The growing knowledge in tumor immunology has evolved rapidly, starting from unspecific generic stimulation of the immune system to more specific approaches based on the availability of tumor antigens. The review covers molecular and cell biology, and pharmaceutical technology of cancer vaccines. Particularly, it is aimed at highlighting the results of cancer vaccines from phase II and III clinical trials, an issue that is of relevance to better understand how cancer vaccines can successfully complement antitumor therapy, including conventional chemotherapy and the recently developed target-based drugs.
Keywords: Cancer, therapeutic vaccines, immunotherapy, clinical trials, investigational drugs, tumor-associated antigen, morbidity, mortality, surgery, chemotherapy, radiation therapy, immune system, exogenous agent, phagocytic cells, neutrophils, monocytes, inflammatory mediators, eosinophils, tumor cells, PROPHYLACTIC, dendritic cell (DC), Food Drug Administration (FDA), hepatitis B virus (HBV), Hepatocellular carcinoma (HCC), papillomaviruses, anus, penis, oropharynx, lipid, carbohydrate, infectious disease, autoimmune disease, Alzheimer's, Xenoantigens, DNA, mammalian cells, oligodeoxinucleotide, Bacteria, monocytogenes, Salmonella typhimurium, Shigella, Mycobacterium, CANCER VACCINES, growth factors, interleukins, anti-tumor, pharmacological, saponin, phospholipid, lymph node, gels, polymer microspheres, endotoxin, pandemic vaccines, memory cells, surface active agents, aluminium hydroxide, Freund's complete adjuvant (FCA), Granulocyte, emulsion, Belagenpumatucel-L, lung cancer, adenocarcinoma, heterogeneity of enrolled patients, glioma, liposomal vaccine, mucin-1, placebo, Breast Cancer, Prostate Cancer, Protein, Pharmexa, pancreatic cancer, Vitespen, Melanoma, constipation, dyspnoea, arthralgia, metastatic colorectal cancer, orphan drug, antigen, pyrexia, symptomatic metastatic, long-term memory immune responses, hormone-refractory prostate, Brain, Temozolomide, vulvar disease, pelvic discomfort, dysplasias, Hodgkin's Lymphoma, lymphotoxic molecules, hyperstimulation
Current Cancer Drug Targets
Title: Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Volume: 11 Issue: 1
Author(s): S. Cecco, E. Muraro, E. Giacomin, D. Martorelli, R. Lazzarini, P. Baldo and R. Dolcetti
Affiliation:
Keywords: Cancer, therapeutic vaccines, immunotherapy, clinical trials, investigational drugs, tumor-associated antigen, morbidity, mortality, surgery, chemotherapy, radiation therapy, immune system, exogenous agent, phagocytic cells, neutrophils, monocytes, inflammatory mediators, eosinophils, tumor cells, PROPHYLACTIC, dendritic cell (DC), Food Drug Administration (FDA), hepatitis B virus (HBV), Hepatocellular carcinoma (HCC), papillomaviruses, anus, penis, oropharynx, lipid, carbohydrate, infectious disease, autoimmune disease, Alzheimer's, Xenoantigens, DNA, mammalian cells, oligodeoxinucleotide, Bacteria, monocytogenes, Salmonella typhimurium, Shigella, Mycobacterium, CANCER VACCINES, growth factors, interleukins, anti-tumor, pharmacological, saponin, phospholipid, lymph node, gels, polymer microspheres, endotoxin, pandemic vaccines, memory cells, surface active agents, aluminium hydroxide, Freund's complete adjuvant (FCA), Granulocyte, emulsion, Belagenpumatucel-L, lung cancer, adenocarcinoma, heterogeneity of enrolled patients, glioma, liposomal vaccine, mucin-1, placebo, Breast Cancer, Prostate Cancer, Protein, Pharmexa, pancreatic cancer, Vitespen, Melanoma, constipation, dyspnoea, arthralgia, metastatic colorectal cancer, orphan drug, antigen, pyrexia, symptomatic metastatic, long-term memory immune responses, hormone-refractory prostate, Brain, Temozolomide, vulvar disease, pelvic discomfort, dysplasias, Hodgkin's Lymphoma, lymphotoxic molecules, hyperstimulation
Abstract: The topic of this review covers a very important branch of cancer research, cancer vaccination. The growing knowledge in tumor immunology has evolved rapidly, starting from unspecific generic stimulation of the immune system to more specific approaches based on the availability of tumor antigens. The review covers molecular and cell biology, and pharmaceutical technology of cancer vaccines. Particularly, it is aimed at highlighting the results of cancer vaccines from phase II and III clinical trials, an issue that is of relevance to better understand how cancer vaccines can successfully complement antitumor therapy, including conventional chemotherapy and the recently developed target-based drugs.
Export Options
About this article
Cite this article as:
Cecco S., Muraro E., Giacomin E., Martorelli D., Lazzarini R., Baldo P. and Dolcetti R., Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives, Current Cancer Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/156800911793743664
DOI https://dx.doi.org/10.2174/156800911793743664 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development
Current Computer-Aided Drug Design Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Effects of Brain IKKβ Gene Silencing by Small Interfering RNA on P-Glycoprotein Expression and Brain Damage in the Rat Kainic Acid-Induced Seizure Model
CNS & Neurological Disorders - Drug Targets Advances of Bioinformatics Applied to Development and Evaluation of Boron-Containing Compounds
Current Organic Chemistry Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling
Current Medicinal Chemistry Gynaecological Cancer Diagnostics: 99mTc-Cisplatin Complex as a Future Approach for Early, Prompt and Efficient Diagnosis of Gynaecological Cancer
Current Medical Imaging Overview of Pediatric Epilepsy
Current Pediatric Reviews Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry Celastrus Orbiculatus Extract Potentiates the Sensitivity of Cisplatin Via Caspase-Depenent Apoptosis in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA Cardiac ATP-Sensitive Potassium Channels: A Potential Target for an Anti-Ischaemic Pharmacological Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry MicroRNA Functions and Potential Clinical Utility in Glioblastoma
Current Signal Transduction Therapy Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Boronated DNA-Binding Compounds as Potential Agents for Boron Neutron Capture Therapy
Mini-Reviews in Medicinal Chemistry Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology